Subscribe
shutterstock_1448545871_jhvephoto
JHVEphoto / Shutterstock.com
5 January 2021AmericasMuireann Bolger

Teva fails to reclassify MS drug to thwart generics

Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone (glatiramer acetate) as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Actavis and Teva sued over narcotic addiction generic
1 March 2017   Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.
Asia
Teva buys Allergan Generics in $40bn deal
27 July 2015   Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Actavis and Teva sued over narcotic addiction generic
1 March 2017   Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.
Asia
Teva buys Allergan Generics in $40bn deal
27 July 2015   Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.

More on this story

Americas
Actavis and Teva sued over narcotic addiction generic
1 March 2017   Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.
Asia
Teva buys Allergan Generics in $40bn deal
27 July 2015   Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York